PSB 0777 ammonium salt
Potent adenosine A2A receptor full agonist (Ki = 44.4 nM for rat brain striatal A2A receptors). Exhibits subtype selectivity for A2A receptors over A1, A2B and A3 receptors (Ki ≥ 10 000 nM for rat A1, human A2B and human A3 receptors). Potentiates acetylcholine-induced contractions in ex vivo rat ileum/jejunum segments.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 500.55. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2 mL||9.99 mL||19.98 mL|
|5 mM||0.4 mL||2 mL||4 mL|
|10 mM||0.2 mL||1 mL||2 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
If you know of a relevant reference for PSB 0777 ammonium salt, please let us know.
View Related Products by Product Action
Keywords: Adenosine A2A receptors agonists potent subtypes selective PSB0777 ammonium salt Adenosine A2A Receptors
Citations for PSB 0777 ammonium salt
Citations are publications that use Tocris products.
Currently there are no citations for PSB 0777 ammonium salt. Do you know of a great paper that uses PSB 0777 ammonium salt from Tocris? If so please let us know.
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.